A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study

被引:3
|
作者
Sheehan, Rory [1 ]
Strydom, Andre [2 ]
Marston, Louise [3 ]
Morant, Nicola [1 ]
Fiori, Federico [4 ]
Santosh, Paramala [5 ]
Hassiotis, Angela [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England
[3] UCL, Res Dept Primary Care & Populat Hlth, London, England
[4] Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, London, England
[5] Kings Coll London, Dept Child & Adolescent Psychiat, London, England
来源
BMJ OPEN | 2019年 / 9卷 / 12期
基金
美国国家卫生研究院;
关键词
CHALLENGING BEHAVIOR; PEOPLE; PREVALENCE; MANAGEMENT; PATIENT; IMPACT;
D O I
10.1136/bmjopen-2019-033827
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate the feasibility of delivering structured psychotropic medication review in community services for adults with intellectual disability (ID). Design Single-arm feasibility study conducted over a 6-month period. Setting Specialist community ID teams in England. Participants Psychiatrists working with adults with ID and adults with ID who had been prescribed psychotropic medication. Intervention A structured web-based psychotropic medication review tool (the HealthTracker-based structured medication review) comprising measures of therapeutic benefit and adverse side-effects was made available for use by psychiatrists in routine clinic appointments. A summary measure of medication effectiveness was graphically presented to aid discussion and decision-making. Main outcome measures Feasibility metrics including number of people with ID referred, eligible and recruited, and uptake of the medication review tool in naturalistic clinical settings. Psychiatrist and patient feedback was collected to assess acceptability of the intervention and suggestions for development. Results Fifteen psychiatrists from five clinical teams took part. In total 94 potentially eligible people with ID were referred, of whom 79 (84%) were recruited and together underwent 97 medication reviews over the 6-month study period. Feedback from participants with ID was favourable. Psychiatrists indicated that the HealthTracker-based structured medication review was broadly acceptable and suggested adaptations to improve integration with existing information technology systems and to enhance patient involvement in the review. Conclusions Structured psychotropic medication review can be used in community services for adults with ID as part of a programme of medication optimisation. It would be feasible to test clinical and patient outcomes of the HealthTracker-based medication review in a randomised clinical trial.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Management of psychotropic medications in adults with intellectual disability: a scoping review
    Costello, Ashley
    Hudson, Eithne
    Morrissey, Susan
    Sharma, Drona
    Kelly, Dervla
    Doody, Owen
    ANNALS OF MEDICINE, 2022, 54 (01) : 2486 - 2499
  • [32] In-home comprehensive medication reviews for adults with intellectual or developmental disability: A pilot study
    Erickson, Steven R.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (06) : E279 - E291
  • [33] Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study
    Chitty, Kate M.
    Evans, Elizabeth
    Torr, Jennifer J.
    Iacono, Teresa
    Brodaty, Henry
    Sachdev, Perminder
    Trollor, Julian N.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 (04): : 352 - 362
  • [34] Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour
    Deb, S.
    Unwin, G.
    Deb, T.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2015, 59 (01) : 11 - 25
  • [35] Psychotropic medication for challenging behaviour in people with intellectual disability: Results of an online survey of family carers
    Sheehan, R.
    Kimona, K.
    Giles, A.
    Cooper, V.
    Hassiotis, A.
    EUROPEAN PSYCHIATRY, 2018, 48 : S240 - S240
  • [36] IMPROVING PSYCHOTROPIC MEDICATION PRESCRIBING IN PEOPLE WITH INTELLECTUAL DISABILITY IN UK PRIMARY CARE: AN EDUCATIONAL INTERVENTION
    Shankar, R.
    Wilcock, M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 678 - 678
  • [37] Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey
    Perry, B. I.
    Kwok, H. F.
    Mendis, J.
    Purandare, K.
    Wijeratne, A.
    Manjubhashini, S.
    Dasari, M.
    Esan, F.
    Gunaratna, I.
    Naseem, R. A.
    Hoare, S.
    Chester, V.
    Roy, A.
    Devapriam, J.
    Alexander, R.
    Cooray, S. E.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2018, 62 (02) : 140 - 149
  • [38] Medication burden and frailty in older adults with intellectual disability: An observational cross-sectional study
    O'Connell, Juliette
    Henman, Martin C.
    McMahon, Niamh
    Burke, Eilish
    McCallion, Philip
    McCarron, Mary
    O'Dwyer, Maire
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (04) : 482 - 492
  • [39] International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities
    Deb, Shoumitro
    Kwok, Henry
    Bertelli, Marco
    Salvador-Carulla, Luis
    Bradley, Elspeth
    Torr, Jennifer
    Barnhill, Jarret
    WORLD PSYCHIATRY, 2009, 8 (03) : 181 - 186
  • [40] Transitional challenges: Psychotropic medication and residential setting among young adults with intellectual disabilities
    Houseworth, James
    Ticha, Renata
    Pettingell, Sandra L.
    Stancliffe, Roger J.
    Bershadsky, Julie
    JOURNAL OF POLICY AND PRACTICE IN INTELLECTUAL DISABILITIES, 2024, 21 (03)